What is the Plasmid-Borne AmpC Gene?
The plasmid-borne ampC gene is a mobile genetic element encoding AmpC β-lactamase enzymes that confer resistance to penicillins, cephalosporins (including third-generation), cephamycins, and aztreonam, and critically, this resistance is not inhibited by classic β-lactamase inhibitors like clavulanic acid.
Mechanism and Clinical Significance
The plasmid-mediated AmpC (pAmpC) represents a particularly concerning resistance mechanism because:
- Unlike chromosomal AmpC (naturally present in organisms like Enterobacter, Citrobacter, and Serratia), plasmid-borne ampC genes are highly transmissible between different bacterial species 1
- These genes likely originated from chromosomal AmpC of certain Gram-negative bacteria and were subsequently mobilized to transmissible plasmids 2
- The plasmid location enables expression in larger quantities and facilitates horizontal gene transfer to organisms that don't naturally produce AmpC 3
Key Bacterial Hosts
Plasmid-mediated AmpC is increasingly recognized in organisms where it's not naturally chromosomal:
- 5-10% of oxyimino-lactam-resistant K. pneumoniae produce plasmid-mediated AmpC rather than ESBL 1
- E. coli and K. pneumoniae are the most frequent carriers 3, 2
- Also detected in Enterobacter species 1
Resistance Profile
Organisms carrying plasmid-borne ampC demonstrate:
- Resistance to: All penicillins, third-generation cephalosporins (ceftazidime, ceftriaxone, cefotaxime), cephamycins (cefoxitin, cefotetan), and aztreonam 1, 3
- Not inhibited by: Clavulanic acid, sulbactam, or tazobactam (classic β-lactamase inhibitors) 3, 2
- Usually susceptible to: Carbapenems (imipenem, meropenem, ertapenem), though resistance can develop through additional mechanisms like porin loss 1
Major Gene Families
Six main plasmid-mediated AmpC families have been identified 3, 2, 4, 5:
- CIT (most common, derived from Citrobacter freundii) 3, 6
- DHA (from Morganella morganii)
- MOX (from Aeromonas species)
- FOX (from Aeromonas species)
- EBC (from Enterobacter cloacae)
- ACC (from Hafnia alvei)
Clinical Detection Challenges
A critical pitfall: Plasmid-mediated AmpC producers may appear susceptible to third-generation cephalosporins by standard testing but can develop resistance during therapy through gene upregulation 1. This differs from ESBL producers, which typically show clear resistance patterns.
Co-occurrence with Other Resistance Mechanisms
- 41.9% of AmpC producers also carry ESBL genes 5
- Plasmids encoding AmpC often carry additional resistance genes for aminoglycosides and other drug classes 1, 6
- The combination of ESBL and AmpC production significantly narrows treatment options
Treatment Implications
Carbapenems remain the most reliable option for serious infections caused by plasmid-mediated AmpC producers 1. However, strains can become carbapenem-resistant through:
- Loss of outer membrane porins (OprD) 1
- Acquisition of additional carbapenemase genes
The newer β-lactam/β-lactamase inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam) show activity against many AmpC producers, though avibactam's spectrum specifically targets certain AmpC types 7.
Epidemiological Importance
Detection rates vary globally, with studies showing 18.3-32.6% of cefoxitin-resistant Gram-negative isolates carrying plasmid-mediated ampC genes 3, 2. The transmissibility via plasmids makes this a significant infection control concern, particularly in healthcare settings where 85% of AmpC-producing isolates cause hospital-acquired infections 5.